138 related articles for article (PubMed ID: 24948620)
1. Can Treg elimination enhance NK cell therapy for AML?
Rooney CM
Blood; 2014 Jun; 123(25):3848-9. PubMed ID: 24948620
[TBL] [Abstract][Full Text] [Related]
2. Clearance of acute myeloid leukemia by haploidentical natural killer cells is improved using IL-2 diphtheria toxin fusion protein.
Bachanova V; Cooley S; Defor TE; Verneris MR; Zhang B; McKenna DH; Curtsinger J; Panoskaltsis-Mortari A; Lewis D; Hippen K; McGlave P; Weisdorf DJ; Blazar BR; Miller JS
Blood; 2014 Jun; 123(25):3855-63. PubMed ID: 24719405
[TBL] [Abstract][Full Text] [Related]
3. NK cell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses.
Salagianni M; Lekka E; Moustaki A; Iliopoulou EG; Baxevanis CN; Papamichail M; Perez SA
J Immunol; 2011 Mar; 186(6):3327-35. PubMed ID: 21317394
[TBL] [Abstract][Full Text] [Related]
4. Activated natural killer cells from patients with acute myeloid leukemia are cytotoxic against autologous leukemic blasts in NOD/SCID mice.
Siegler U; Kalberer CP; Nowbakht P; Sendelov S; Meyer-Monard S; Wodnar-Filipowicz A
Leukemia; 2005 Dec; 19(12):2215-22. PubMed ID: 16224486
[TBL] [Abstract][Full Text] [Related]
5. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
6. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
7. A phase II clinical trial of adoptive transfer of haploidentical natural killer cells for consolidation therapy of pediatric acute myeloid leukemia.
Nguyen R; Wu H; Pounds S; Inaba H; Ribeiro RC; Cullins D; Rooney B; Bell T; Lacayo NJ; Heym K; Degar B; Schiff D; Janssen WE; Triplett B; Pui CH; Leung W; Rubnitz JE
J Immunother Cancer; 2019 Mar; 7(1):81. PubMed ID: 30894213
[TBL] [Abstract][Full Text] [Related]
8. Diphtheria toxin-interleukin-3 fusion protein (DT(388)IL3) prolongs disease-free survival of leukemic immunocompromised mice.
Black JH; McCubrey JA; Willingham MC; Ramage J; Hogge DE; Frankel AE
Leukemia; 2003 Jan; 17(1):155-9. PubMed ID: 12529673
[TBL] [Abstract][Full Text] [Related]
9. The role of recombinant interleukin-2 in therapy for hematologic malignancies.
Dutcher JP; Wiernik PH
Semin Oncol; 1993 Dec; 20(6 Suppl 9):33-40. PubMed ID: 8284690
[No Abstract] [Full Text] [Related]
10. Diphtheria toxin fusion proteins.
Foss FM; Saleh MN; Krueger JG; Nichols JC; Murphy JR
Curr Top Microbiol Immunol; 1998; 234():63-81. PubMed ID: 9670613
[No Abstract] [Full Text] [Related]
11. Targeting diphtheria toxin to growth factor receptors.
Murphy JR; vanderSpek JC
Semin Cancer Biol; 1995 Oct; 6(5):259-67. PubMed ID: 8562903
[TBL] [Abstract][Full Text] [Related]
12. Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Farag SS; George SL; Lee EJ; Baer M; Dodge RK; Becknell B; Fehniger TA; Silverman LR; Crawford J; Bloomfield CD; Larson RA; Schiffer CA; Caligiuri MA
Clin Cancer Res; 2002 Sep; 8(9):2812-9. PubMed ID: 12231521
[TBL] [Abstract][Full Text] [Related]
13. Recombinant fusion toxins--a new class of targeted biologic therapeutics.
Woodworth TG; Nichols JC
Cancer Treat Res; 1993; 68():145-60. PubMed ID: 8105849
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-2 receptor-directed therapies: antibody-or cytokine-based targeting molecules.
Strom TB; Kelley VR; Murphy JR; Nichols J; Woodworth TG
Annu Rev Med; 1993; 44():343-53. PubMed ID: 8476255
[TBL] [Abstract][Full Text] [Related]
15. Initial clinical experiences with an interleukin-2 fusion toxin (DAB486-IL-2).
Meneghetti CM; LeMaistre CF
Targeted Diagn Ther; 1992; 7():395-401. PubMed ID: 1633301
[No Abstract] [Full Text] [Related]
16. Treatment with a diphtheria toxin-related interleukin 2 fusion protein prolongs cardiac allograft survival in mice.
Barrett LV; Murphy JR; Strom TB; Kirkman RL
Transplant Proc; 1989 Feb; 21(1 Pt 1):1130-1. PubMed ID: 2650076
[No Abstract] [Full Text] [Related]
17. Antibody response to DT-GM, a novel fusion toxin consisting of a truncated diphtheria toxin (DT) linked to human granulocyte-macrophage colony stimulating factor (GM), during a phase I trial of patients with relapsed or refractory acute myeloid leukemia.
Hall PD; Virella G; Willoughby T; Atchley DH; Kreitman RJ; Frankel AE
Clin Immunol; 2001 Aug; 100(2):191-7. PubMed ID: 11465948
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia.
Sandoval-Borrego D; Moreno-Lafont MC; Vazquez-Sanchez EA; Gutierrez-Hoya A; López-Santiago R; Montiel-Cervantes LA; Ramírez-Saldaña M; Vela-Ojeda J
Arch Med Res; 2016 Jan; 47(1):55-64. PubMed ID: 26876298
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2 corrects defective NK activity of patients with leukemia.
Lotzová E; Savary CA
Comp Immunol Microbiol Infect Dis; 1986; 9(2-3):169-75. PubMed ID: 3491726
[TBL] [Abstract][Full Text] [Related]
20. Cytokine-induced killer cells: NK-like T cells with cytotolytic specificity against leukemia.
Linn YC; Hui KM
Leuk Lymphoma; 2003 Sep; 44(9):1457-62. PubMed ID: 14565644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
